Transforming growth factor-β as a treatment target in renal diseases

Journal of Nephrology

Volumn 22, Issue 6, 2009, Pages 708-715

  Fukuda, Noboru ^a,b   Tahira, Yoshiko ^a   Matsuda, Hiroyuki ^b   Matsumoto, Koichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; Epithelial mesenchymal transformation; Extracellular matrix; Gene therapy; TGF

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; DECORIN; HAMMERHEAD RIBOZYME; IMIDAZOLE; OSTEOGENIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; POLYAMIDE; PROTEIN KINASE C; PYRROLE; SCATTER FACTOR; SMAD2 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ACUTE GLOMERULONEPHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; GENE SILENCING; GENE THERAPY; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FIBROSIS; MESANGIUM CELL; NEPHROSCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAT; RENAL PROTECTION; RIBOZYME VECTOR; VASCULAR SMOOTH MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE SILENCING; GENE THERAPY; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; RATS; RNA, CATALYTIC; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 72149097861     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Kiehntopf M, Brach MA, Licht T, et al. Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J. 1994;13:4645-4652.
2. Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 1998;9:49-61.
3. Vale W, Hsueh A, Rivier C, Yu J. The inhibin/activin family of hormones and growth factors. In: Sporn MB, Roberts AB, eds. Peptide growth factors and their receptors. Heidelberg: Springer-Verlag; 1990:211-248.
4. Smith JC. Mesoderm-inducing factors in early vertebrate development. EMBO J. 1993;12:4463-4470.
5. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18-25.
6. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242:1528-1534.
7. Basler K, Edlund T, Jessell TM, Yamada T. Control of cell pattern in the neural tube: regulation of cell differentiation by dorsalin-1, a novel TGF-beta family member. Cell. 1993;73:687-702.
8. Godin RE, Takaesu NT, Robertson EJ, Dudley AT. Regulation of BMP7 expression during kidney development. Development. 1998;125:3473-3482.
9. Lund RJ, Davies MR, Hruska KA. Bone morphogenetic protein 7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens. 2002;11:31-36.
10. Fukuda N, Kubo A, Izumi Y, Soma M, Kanmatsuse K. Characteristics and expression of transforming growth factor-β receptor subtypes on vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens. 1995;13:831-837.
11. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261:4337-4345.
12. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res. 1989;49:2533-2553.
13. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis: possible role in expansion of the mesangial extracellular matrix. J Clin Invest. 1990;86:453-462.
14. Derynck R. TGF-β-receptor-mediated signaling. Trends Biochem Sci. 1994;19:548-553.
15. Attisano L, Wrana JL, Lopez-Casillas F, Massague J. TGF-β receptors and actions. Biochem Biophys Acta. 1994;1222:71-80.
16. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature. 1994;370:341-347.
17. Fukuda N, Hu WY, Kubo A, et al. Abnormal regulation of TGF-β receptors on vascular smooth muscle cells from spontaneously hypertensive rats by angiotensin II. Hypertension. 1998;31:672-677.
18. Fukuda N, Hu WY, Satoh C, et al. Contribution of synthetic phenotype on the enhanced angiotensin II-generating system in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens. 1999;17:1099-1107.
19. Stouffer GA, Owens GK. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-β. Circ Res. 1992;70:820-828.
20. Massague J. TGF-β signal transduction. Annu Rev Biochem. 1998;67:753-791.
21. Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGF-β-inducible transcriptional complexes. Genes Dev. 1997;11:3157-3167.
22. Grande JP. Role of transforming growth factor-β in tissue injury and repair. Proc Soc Exp Biol Med. 1997;214:27-40.
23. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor TGF-β1 positively regulates its own expression in normal and transformed cells. J Biol Chem. 1988;263:7741-7746.
24. Kim SJ, Angel P, Lafyatis R, et al. Autoinduction of transforming growth factor β1 is mediated by the AP-1 complex. Mol Cell Biol. 1990;10:1492-1497.
25. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-1292.
26. Gentry LE, Webb NR, Lim GJ, et al. Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol Cell Biol. 1987;7:3418-3427.
27. Gentry LE, Lioubin MN, Purchio AF, Marquardt H. Molecular events in the processing of recombinant type 1 pre-protransforming growth factor β to the mature polypeptide. Mol Cell Biol. 1988;8:4162-4168.
28. Harpel JG, Metz CN, Kojima S, Rifkin DB. Control of transforming growth factor-β activity: latency vs. activation. Prog Growth Factor Res. 1992;4:321-335.
29. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-β. J Biol Chem. 1999;274:13586-13593.
30. Sporn MB, Roberts AB. TGF-beta: problems and prospects. Cell Regul. 1990;1:875-882.
31. Barnard JA, Lyons RM, Moses HL. The cell biology of transforming growth factor β. Biochim Biophys Acta. 1990;1032:79-87.
32. Miyazono K, Ten Dijke P, Ichijo H, Heldin CH. Receptors for transforming growth factor-beta. Adv Immunol. 1994;55:181-220.
33. Wilcox JN. Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. Am J Cardiol. 1993;72:88E-95E.
34. Isaka Y, Akagi Y, Ando Y, et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 1999;55:465-475.
35. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature. 1990;346:371-374.
36. Border WA, Noble NA. Cytokines in kidney disease: the role of transforming growth factor-β. Am J Kidney Dis. 1993;22:105-113.
37. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol. 1994;266:F829-F842.
38. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288-296.
39. Yokoi H, Sugawara A, Mukoyama M, et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor-β: a potential target for preventing renal fibrosis. Am J Kidney Dis. 2001;38:S134-S138.
40. Gould SE, Day M, Jones SS, Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int. 2002;61:51-60.
41. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003;9:964-968.
42. Takeuchi K, Nakamura N, Cook NS, Pratt RE, Dzau VJ. Angiotensin II can regulate gene expression by the AP-1 binding sequence via protein kinase C dependent pathway. Biochem Biophys Res Commun. 1990;172:1189-1194.
43. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996;49:578-597.
44. Border WA, Noble NA. Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension. 1998;31:181-188.
45. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945.
46. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
47. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
48. Ruiz-Ortega M, Gonzalez S, Seron D, et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int. 1995;48:1778-1791.
49. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int. 1997; 51:1553-1567.
50. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature. 1990; 346:281-284.
51. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med. 1996;2:418-423.
52. Schaefer L, Macakova K, Raslik I, et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol. 2002;160:1181-1191.
53. Hogan BL. Bone morphogenic proteins in development. Curr Opin Genet Dev. 1996;6:432-438.
54. Yang J, Dai C, Liu Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol. 2003;163:621-632.
55. Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol. 2003;284:F349-F357.
56. Tahira Y, Fukuda N, Endo M, et al. Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor beta1 mRNA efficiently ameliorates renal injury in hypertensive rats. J Hypertens. 2007;25:671-678.
57. Trauger JW, Baird EE, Dervan PB. Recognition of DNA by designed ligands at subnanomolar concentrations. Nature. 1996;382:559-561.
58. White S, Baird EE, Dervan PB. On the pairing rules for recognition in the minor groove of DNA by pyrrole-imidazole polyamides. Chem Biol. 1997;4:569-578.
59. White S, Szewczyk JW, Turner JM, Baird EE, Dervan PB. Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands. Nature. 1998;391:468-471.
60. Gottesfeld JM, Neely L, Trauger JW, Baird EE, Dervan PB. Regulation of gene expression by small molecules. Nature. 1997;387:202-205.
61. Lai YM, Fukuda N, Ueno T, et al. Synthetic pyrroleimidazole polyamide inhibits expression of the human transforming growth factor-β1 gene. J Pharmacol Exp Ther. 2005;315:571-575.
62. Matsuda H, Fukuda N, Ueno T, et al. Development of gene silencing pyrrole-imidazole polyamide targeted to the TGF-β1 promoter for treatment of progressive renal diseases. J Am Soc Nephrol. 2006;17:422-432.